TY  - BOOK
AU  - Dolman, Sarahfaye
AU  - Kolm, Paul
AU  - Weintraub, William S
TI  - Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
PY  - 2022///
KW  - *Cost-Benefit Analysis
KW  - *Eicosapentaenoic Acid/ec [Economics]
KW  - *Eicosapentaenoic Acid/tu [Therapeutic Use]
KW  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/ec [Economics]
KW  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
KW  - *Hyperlipidemias/dt [Drug Therapy]
KW  - *Hyperlipidemias/ec [Economics]
KW  - Aged
KW  - Eicosapentaenoic Acid/aa [Analogs & Derivatives]
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Risk Factors
KW  - MedStar Health Research Institute
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
KW  - Research Support, Non-U.S. Gov't
N2  - Conclusions and Relevance: This study suggests that, both in-trial and over the lifetime, IPE offers better cardiovascular outcomes than standard care in REDUCE-IT participants at common willingness-to-pay thresholds; Design, Setting, and Participants: An in-trial cost-effectiveness analysis was performed using patient-level study data from REDUCE-IT, and a lifetime analysis was performed using a microsimulation model and data from published literature. The study included 8179 patients with hypertriglyceridemia despite stable statin therapy recruited between November 21, 2011, and May 31, 2018. Analyses were performed from a US health care sector perspective. Statistical analysis was performed from March 1, 2018, to October 31, 2021; Importance: The Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial (REDUCE-IT) demonstrated the efficacy of icosapent ethyl (IPE) for high-risk patients with hypertriglyceridemia and known cardiovascular disease or diabetes and at least 1 other risk factor who were treated with statins; Interventions: Patients were randomly assigned to IPE, 4 g/d, or placebo and were followed up for a median of 4.9 years (IQR, 3.5-5.3 years). The cost of IPE was; Main Outcomes and Measures: Main outcomes were incremental quality-adjusted life-years (QALYs), total direct health care costs (2019 US dollars), and cost-effectiveness; Objective: To estimate the cost-effectiveness of IPE compared with standard care for high-risk patients with hypertriglyceridemia despite statin treatment; Results: A total of 4089 patients (2927 men [71.6%]; median age, 64.0 years [IQR, 57.0-69.0 years]) were randomly assigned to receive IPE, and 4090 patients (2895 men [70.8%]; median age, 64.0 years [IQR, 57.0-69.0 years]) were randomly assigned to receive standard care. Treatment with IPE yielded more QALYs than standard care both in trial (3.34 vs 3.27; mean difference, 0.07 [95% CI, 0.01-0.12]) and over a lifetime projection (10.59 vs 10.35; mean difference, 0.24 [95% CI, 0.15-0.33]). In-trial, total health care costs were higher with IPE using either SSR cost (
UR  - https://dx.doi.org/10.1001/jamanetworkopen.2021.48172
ER  -